Literature DB >> 31678162

Pathomechanisms in the neuronal ceroid lipofuscinoses.

Hemanth R Nelvagal1, Jenny Lange2, Keigo Takahashi3, Marta A Tarczyluk-Wells4, Jonathan D Cooper3.   

Abstract

The neuronal ceroid lipofuscinoses (NCLs) are a group of inherited neurodegenerative lysosomal storage disorders (LSDs), traditionally grouped together based on shared clinical symptoms. The recent emergence of new forms of NCL along with an improved understanding of endo-lysosomal system function have necessitated the reassessment of their classification and pathogenesis. Novel clinical findings, as well as observations in various animal models of NCL, have revealed significant pathological changes in regions outside the brain, as well as progression of disease along connected anatomical pathways. The characterization of animal models of NCLs has not only highlighted the vulnerability of certain neuron populations but has also revealed glial cells to be adversely affected and actively contribute to disease progression. While the lysosome has been thought of as being the 'waste-disposal' unit of the cell, recent evidence of the endo-lysosomal system playing a crucial role in nutrient sensing and cellular homeostasis have shown that NCL mutations have far-ranging effects on cellular functions including autophagy and synaptic dysfunction. The discovery of the machinery controlling endo-lysosomal function via transcription factor EB (TFEB) and mTORC1, have also shed light on potential mechanisms by which NCL mutations may exert their effect. While the NCLs share many common down-stream pathologies, there is a growing body of evidence for unique pathogenic pathways in each form. In light of the rapid advances in therapeutic strategies for the NCLs and LSDs, these new lessons learnt about unique NCL pathomechanisms will be key for informing the targeting, timing and strategies for future treatments.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Glial dysfunction; Lysosomal storage disorders; Neurodegeneration; Neuronal ceroid lipofuscinoses; Pathogenesis; Synaptopathy

Year:  2019        PMID: 31678162     DOI: 10.1016/j.bbadis.2019.165570

Source DB:  PubMed          Journal:  Biochim Biophys Acta Mol Basis Dis        ISSN: 0925-4439            Impact factor:   5.187


  16 in total

Review 1.  Recent Insight into the Genetic Basis, Clinical Features, and Diagnostic Methods for Neuronal Ceroid Lipofuscinosis.

Authors:  Konrad Kaminiów; Sylwia Kozak; Justyna Paprocka
Journal:  Int J Mol Sci       Date:  2022-05-20       Impact factor: 6.208

2.  Ppt1-deficiency dysregulates lysosomal Ca++ homeostasis contributing to pathogenesis in a mouse model of CLN1 disease.

Authors:  Avisek Mondal; Abhilash P Appu; Tamal Sadhukhan; Maria B Bagh; Rafael M Previde; Sriparna Sadhukhan; Stanko Stojilkovic; Aiyi Liu; Anil B Mukherjee
Journal:  J Inherit Metab Dis       Date:  2022-03-17       Impact factor: 4.750

Review 3.  Glial Dysfunction and Its Contribution to the Pathogenesis of the Neuronal Ceroid Lipofuscinoses.

Authors:  Keigo Takahashi; Hemanth R Nelvagal; Jenny Lange; Jonathan D Cooper
Journal:  Front Neurol       Date:  2022-04-04       Impact factor: 4.086

4.  Novel likely disease-causing CLN5 variants identified in Pakistani patients with neuronal ceroid lipofuscinosis.

Authors:  Beenish Azad; Stephanie Efthymiou; Tipu Sultan; Marcello Scala; Javeria Raza Alvi; Caroline Neuray; Natalia Dominik; Asma Gul; Henry Houlden
Journal:  J Neurol Sci       Date:  2020-04-07       Impact factor: 3.181

Review 5.  Cathepsins in the Pathophysiology of Mucopolysaccharidoses: New Perspectives for Therapy.

Authors:  Valeria De Pasquale; Anna Moles; Luigi Michele Pavone
Journal:  Cells       Date:  2020-04-15       Impact factor: 6.600

Review 6.  Molecular networking in the neuronal ceroid lipofuscinoses: insights from mammalian models and the social amoeba Dictyostelium discoideum.

Authors:  Robert J Huber
Journal:  J Biomed Sci       Date:  2020-05-20       Impact factor: 8.410

Review 7.  Current Clinical Applications of In Vivo Gene Therapy with AAVs.

Authors:  Jerry R Mendell; Samiah A Al-Zaidy; Louise R Rodino-Klapac; Kimberly Goodspeed; Steven J Gray; Christine N Kay; Sanford L Boye; Shannon E Boye; Lindsey A George; Stephanie Salabarria; Manuela Corti; Barry J Byrne; Jacques P Tremblay
Journal:  Mol Ther       Date:  2020-12-10       Impact factor: 11.454

8.  Urine proteomics analysis of patients with neuronal ceroid lipofuscinoses.

Authors:  Katharina Iwan; Robert Clayton; Philippa Mills; Barbara Csanyi; Paul Gissen; Sara E Mole; David N Palmer; Kevin Mills; Wendy E Heywood
Journal:  iScience       Date:  2020-12-31

9.  Neuronal Ceroid Lipofuscinosis Type 6 (CLN6) clinical findings and molecular diagnosis: Costa Rica's experience.

Authors:  R Badilla-Porras; A Echeverri-McCandless; J M Weimer; A Ulate-Campos; A Soto-Rodríguez; A Gutiérrez-Mata; L Hernández-Con; S Bogantes-Ledezma; A Balmaceda-Meza; J Brudvig; A Sanabria-Castro
Journal:  Orphanet J Rare Dis       Date:  2022-01-10       Impact factor: 4.123

10.  Tripeptidyl Peptidase 1 (TPP1) Deficiency in a 36-Year-Old Patient with Cerebellar-Extrapyramidal Syndrome and Dilated Cardiomyopathy.

Authors:  Agnieszka Ługowska; Joanna K Purzycka-Olewiecka; Rafał Płoski; Grażyna Truszkowska; Maciej Pronicki; Paulina Felczak; Mateusz Śpiewak; Aleksandra Podlecka-Piętowska; Martyna Sitek; Zofia T Bilińska; Przemysław Leszek; Małgorzata Bednarska-Makaruk
Journal:  Life (Basel)       Date:  2021-12-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.